Alzheimer's is a neurodegenerative disease that primarily affects older adults and is associated with the aging population. As societies age, the number of dementia cases, particularly Alzheimer's, increases. However, some developed countries have seen a decline in the incidence of the disease due to improvements in education, sanitation, and lifestyle. Despite these advancements, Alzheimer's remains a significant challenge for the scientific community and healthcare systems due to the complexity of its causes and the lack of effective treatments. Currently, more...

We are pleased to announce our participation in an innovative project featured in CREA. Below is the text of the publication: Biocross has initiated a study to evaluate the quantification of Apolipoprotein E4 (ApoE4) as a risk marker for Alzheimer's disease, cardiovascular diseases, and type II diabetes mellitus. In this project, which involves collaboration between various Spanish and Mexican institutions, Biocross has provided the Imserso reference center with a turbidity analyzer laboratory equipment for the study's development. This research opens up the...

Dr. Pablo Cabello Albendea, from the Hospital Ramón y Cajal, emphasizes the importance of reducing the levels of the APOE4 protein in carriers to treat Alzheimer's disease. A recent study by the “National Institute of Aging” suggests that reducing APOE4 can be therapeutic and that it is crucial to identify and quantify this protein to personalize treatments. Additionally, new gene therapies and strategies combined with anti-amyloid treatments are being explored. Research needs to address when and how to apply...

The company Biocross has developed two innovative blood tests, e4Risk® and e4Quant®, which identify and quantify the presence of the APOE4 gene, related to various metabolic and neurodegenerative diseases such as type 2 diabetes, cardiovascular diseases, and Alzheimer’s. A recent study by the Research Institute of the Hospital de la Santa Creu i Sant Pau in Barcelona revealed that almost all individuals with a duplication of the APOE4 gene develop biomarkers associated with dementia. These tests represent a significant...

The Research Institute of the Hospital de la Santa Creu i Sant Pau in Barcelona has identified a new genetic form of Alzheimer's: the duplication of the APOE4 gene. This discovery highlights the importance of the APOE4 gene in Alzheimer's research. Biocross aims to position APOE4 as a reference biomarker for the risk/prognosis of diseases related to alterations in lipid metabolism (Alzeimer's, cardiovascular diseases, Diabetes Mellitus Type II, pathologies that grow above the population average) and to identify and quantify...